Valuation : Penumbra, Inc.

Market Cap 12.58B 10.81B 10.17B 9.28B 17.32B 1,192B 17.41B 121B 46.63B 609B 47.22B 46.19B 1,939B P/E 2026 *
72.4x
P/E 2027 * 52.1x
Enterprise Value 12.13B 10.43B 9.81B 8.95B 16.71B 1,150B 16.79B 116B 44.97B 588B 45.54B 44.55B 1,870B EV / Sales 2026 *
7.61x
EV / Sales 2027 * 6.58x
Free-Float
97.1%
Yield 2026 *
-
Yield 2027 * -
1 day+0.08%
1 week-0.94%
Current month-1.03%
1 month-1.91%
3 months-0.40%
6 months-5.84%
Current year+2.85%
1 week 319.18
Extreme 319.175
323.7
1 month 319.18
Extreme 319.175
328.6
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 2004-06-20
President 41 2025-08-31
Director of Finance/CFO 54 2019-12-01
Director TitleAgeSince
Chairman 64 2014-12-31
Chairman 64 2004-12-31
Director/Board Member 59 2015-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Free

Chairperson

3,060 0.0078%
5/19/26 Don

Chief Executive Officer

-77,000 0.1958%
4/2/26 Sell

Director

100 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.08%-0.94%+11.38%+6.58% 12.58B
-0.63%-2.82%+12.15%+25.75% 6.81B
-3.22%-4.38% - - 6.55B
-1.57%-14.12%+20.47%+10.90% 5.7B
-0.16%-4.20%-24.61%+40.54% 4.97B
+0.23%-1.68%-35.72%-21.47% 3.81B
-2.64%-8.02%+29.54%-19.96% 1.96B
+2.75%+0.84%-1.16%+132.68% 1.72B
+0.98%-3.45%+47.37%-17.20% 1.62B
-0.68%+6.89%-5.16%+33.21% 1.4B
Average -0.62%-1.54%+6.03%+21.23% 4.71B
Weighted average by Cap. -0.76%-1.82%+5.17%+15.97%

Financials

2026 *2027 *
Net sales 1.59B 1.37B 1.29B 1.18B 2.19B 151B 2.21B 15.27B 5.91B 77.19B 5.98B 5.85B 246B 1.8B 1.55B 1.46B 1.33B 2.48B 171B 2.49B 17.25B 6.67B 87.21B 6.76B 6.61B 278B
Net income 176M 152M 143M 130M 243M 16.73B 244M 1.69B 654M 8.55B 663M 648M 27.21B 242M 208M 196M 179M 334M 22.97B 336M 2.32B 899M 11.74B 910M 890M 37.37B
Net Debt -447M -384M -362M -330M -616M -42.38B -619M -4.28B -1.66B -21.66B -1.68B -1.64B -68.93B -729M -627M -589M -538M -1B -69.08B -1.01B -6.98B -2.7B -35.31B -2.74B -2.68B -112B
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
26-09-09 US$319.71 +0.14% 62,458
26-09-08 US$319.26 -0.90% 380,769
26-09-04 US$322.17 +0.32% 174,065
26-09-03 US$321.14 -0.51% 313,873
26-09-02 US$322.80 +0.07% 220,280
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
319.26USD
Average target price
361.83USD
Spread / Average Target
+13.34%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!